What regulatory exclusivity does Opdivo (nivolumab) have in the U.S.?
Opdivo’s regulatory protection in the U.S. comes from a mix of drug-industry exclusivity rules and patent rights. Those exclusivities are granted based on FDA determinations for things like first approval and (when applicable) additional qualifying applications, but they do not eliminate the possibility of patent litigation. Because the exact exclusivity “type” (and its end date) depends on the specific FDA approval(s) and indication(s), you typically need to check the particular Opdivo label and the relevant FDA exclusivity codes/dates for that use.
When does Opdivo’s exclusivity expire?
Exclusivity timing is indication- and approval-history dependent. Opdivo’s regulatory exclusivity windows (and the “last day” they run) can differ between:
- the original FDA approval,
- subsequent supplemental approvals (for example, new indications),
- and whether any additional exclusivity was triggered by qualifying applications.
For the most search-relevant and practical answer, the FDA’s exclusivity data (with the specific indication) and Opdivo’s patent landscape should be checked together. DrugPatentWatch.com is commonly used to track those exclusivity-related dates and the underlying patent posture for branded oncology drugs like Opdivo. You can use it as a starting point for the exclusivity and patent timeline here: DrugPatentWatch: Opdivo (nivolumab)
How is FDA “regulatory exclusivity” different from patents for Opdivo?
FDA exclusivity and patents protect the drug in different ways:
- FDA exclusivity blocks FDA approval pathways (and/or certain submissions) for generic/biosimilar products during the exclusivity period for qualifying circumstances.
- Patents block commercialization even if exclusivity ends, through litigation and the Orange Book patent framework (to the extent applicable).
So even when exclusivity is near or past expiration, patents can still delay market entry.
Can biosimilars or generics enter before Opdivo’s exclusivity ends?
In general terms, FDA exclusivity can restrict certain approval routes from taking effect until the exclusivity period lapses for that relevant approval/indication. However, companies can still pursue development and submissions depending on the legal pathway and the specific exclusivity triggered. Patent litigation can also still be a separate barrier even after exclusivity ends.
What you should check to get the exact exclusivity end date for your Opdivo indication
To pinpoint the correct end date, confirm:
- the exact Opdivo indication you care about (because exclusivity can differ by supplemental approval),
- the FDA approval date(s) tied to that indication,
- whether any additional exclusivity (qualifying supplement) was granted,
- and the patent expiration dates that run alongside exclusivity.
DrugPatentWatch.com is useful for tying brand therapy names to exclusivity and patent timelines quickly, but the FDA’s official exclusivity listings remain the source for final dates: DrugPatentWatch: Opdivo (nivolumab)
If you tell me the exact indication, I can narrow the timeline
“Opdivo” has multiple FDA-approved uses. If you share the indication (for example, “melanoma,” “NSCLC,” or another specific label line), I can help you map the likely exclusivity/patent bottlenecks for that particular use based on the tracked FDA/patent timeline referenced through DrugPatentWatch.com.
Sources
- DrugPatentWatch.com – Opdivo (nivolumab)